{"transactions":[{"id":2534629,"issuer":{"id":115177,"kind":"organization","name":"Metacrine, Inc.","symbol":"MTCR"},"owners":[{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":1,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":2,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-26T16:35:03.000Z","date":"2021-10-25","kind":"sale","acquired":false,"shares":540667,"price":1.4907,"value":805972.2969,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.42 to $1.59, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Robert Adelman and Corey Goodman (collectively, the \"Directors\") are each a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd., and the Directors disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2443421,"source":{"system":"sec-edgar","filing":"0001567619-21-018722","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1770835/000156761921018722/doc1.xml","form_type":"4"}},{"id":2534628,"issuer":{"id":115177,"kind":"organization","name":"Metacrine, Inc.","symbol":"MTCR"},"owners":[{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":1,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":2,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":5,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-26T16:35:03.000Z","date":"2021-10-22","kind":"sale","acquired":false,"shares":75035,"price":1.6383,"value":122929.8405,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.62 to $1.66, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Robert Adelman and Corey Goodman (collectively, the \"Directors\") are each a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd., and the Directors disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":2984088,"source":{"system":"sec-edgar","filing":"0001567619-21-018722","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1770835/000156761921018722/doc1.xml","form_type":"4"}},{"id":3025088,"issuer":{"id":115177,"kind":"organization","name":"Metacrine, Inc.","symbol":"MTCR"},"owners":[{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":1,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":2,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Series C Convertible Preferred Stock","published_at":"2020-09-22T17:21:21.000Z","date":"2020-09-18","kind":"exercise","acquired":false,"shares":396089,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Corey Goodman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":396089},"source":{"system":"sec-edgar","filing":"0000905148-20-001037","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1770835/000090514820001037/form4.xml","form_type":"4"}},{"id":3025087,"issuer":{"id":115177,"kind":"organization","name":"Metacrine, Inc.","symbol":"MTCR"},"owners":[{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":1,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":2,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Series B Convertible Preferred Stock","published_at":"2020-09-22T17:21:21.000Z","date":"2020-09-18","kind":"exercise","acquired":false,"shares":472250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Corey Goodman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":472250},"source":{"system":"sec-edgar","filing":"0000905148-20-001037","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1770835/000090514820001037/form4.xml","form_type":"4"}},{"id":3025086,"issuer":{"id":115177,"kind":"organization","name":"Metacrine, Inc.","symbol":"MTCR"},"owners":[{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":1,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":2,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-09-22T17:21:21.000Z","date":"2020-09-18","kind":"exercise","acquired":false,"shares":1960784,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Corey Goodman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1960784},"source":{"system":"sec-edgar","filing":"0000905148-20-001037","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1770835/000090514820001037/form4.xml","form_type":"4"}},{"id":3025085,"issuer":{"id":115177,"kind":"organization","name":"Metacrine, Inc.","symbol":"MTCR"},"owners":[{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":1,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":2,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2020-09-22T17:21:21.000Z","date":"2020-09-18","kind":"exercise","acquired":true,"shares":2829123,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Corey Goodman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":3059123,"source":{"system":"sec-edgar","filing":"0000905148-20-001037","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1770835/000090514820001037/form4.xml","form_type":"4"}},{"id":3025084,"issuer":{"id":115177,"kind":"organization","name":"Metacrine, Inc.","symbol":"MTCR"},"owners":[{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":1,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":2,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":4,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2020-09-22T17:21:21.000Z","date":"2020-09-18","kind":"purchase","acquired":true,"shares":230000,"price":13,"value":2990000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Corey Goodman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":230000,"source":{"system":"sec-edgar","filing":"0000905148-20-001037","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1770835/000090514820001037/form4.xml","form_type":"4"}},{"id":3078927,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":88848,"kind":"person","name":"Adelman Robert J","position":1,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":2,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":4,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":5,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":6,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":7,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Series C Convertible Preferred Stock","published_at":"2020-07-22T01:29:11.000Z","date":"2020-07-16","kind":"exercise","acquired":false,"shares":1052950,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman is a director of venBio Global Strategic GP II, Ltd.  Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1052950},"source":{"system":"sec-edgar","filing":"0000905148-20-000827","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000090514820000827/form4.xml","form_type":"4"}},{"id":3078926,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":88848,"kind":"person","name":"Adelman Robert J","position":1,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":2,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":4,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":5,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":6,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":7,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Series B Convertible Preferred Stock","published_at":"2020-07-22T01:29:11.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":490411,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman is a director of venBio Global Strategic GP II, Ltd.  Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":490411},"source":{"system":"sec-edgar","filing":"0000905148-20-000827","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000090514820000827/form4.xml","form_type":"4"}},{"id":3078925,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":88848,"kind":"person","name":"Adelman Robert J","position":1,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":2,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":4,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":5,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":6,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":7,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-07-22T01:29:11.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":2398588,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman is a director of venBio Global Strategic GP II, Ltd.  Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2398588},"source":{"system":"sec-edgar","filing":"0000905148-20-000827","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000090514820000827/form4.xml","form_type":"4"}},{"id":3078924,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":88848,"kind":"person","name":"Adelman Robert J","position":1,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":2,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":4,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":5,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":6,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":7,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-07-22T01:29:11.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":3100020,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Robert Adelman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3100020},"source":{"system":"sec-edgar","filing":"0000905148-20-000827","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000090514820000827/form4.xml","form_type":"4"}},{"id":3078923,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":88848,"kind":"person","name":"Adelman Robert J","position":1,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":2,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":4,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":5,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":6,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":7,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-07-22T01:29:11.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":78175,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"The shares are held by Robert Adelman directly."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":78175},"source":{"system":"sec-edgar","filing":"0000905148-20-000827","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000090514820000827/form4.xml","form_type":"4"}},{"id":3078922,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":88848,"kind":"person","name":"Adelman Robert J","position":1,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":2,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":4,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":5,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":6,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":7,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2020-07-22T01:29:11.000Z","date":"2020-07-21","kind":"purchase","acquired":true,"shares":3000,"price":19,"value":57000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"The shares are held by Robert Adelman directly."}],"balance_after":99406,"source":{"system":"sec-edgar","filing":"0000905148-20-000827","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000090514820000827/form4.xml","form_type":"4"}},{"id":3078921,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":88848,"kind":"person","name":"Adelman Robert J","position":1,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":2,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":4,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":5,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":6,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":7,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2020-07-22T01:29:11.000Z","date":"2020-07-21","kind":"purchase","acquired":true,"shares":850000,"price":19,"value":16150000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman is a director of venBio Global Strategic GP II, Ltd.  Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":5268325,"source":{"system":"sec-edgar","filing":"0000905148-20-000827","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000090514820000827/form4.xml","form_type":"4"}},{"id":3078920,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":88848,"kind":"person","name":"Adelman Robert J","position":1,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":2,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":4,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":5,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":6,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":7,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2020-07-22T01:29:11.000Z","date":"2020-07-21","kind":"exercise","acquired":true,"shares":3941949,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 476,376 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman is a director of venBio Global Strategic GP II, Ltd.  Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":4418325,"source":{"system":"sec-edgar","filing":"0000905148-20-000827","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000090514820000827/form4.xml","form_type":"4"}},{"id":3078919,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":88848,"kind":"person","name":"Adelman Robert J","position":1,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":2,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":4,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":5,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":6,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":7,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2020-07-22T01:29:11.000Z","date":"2020-07-21","kind":"exercise","acquired":true,"shares":3100020,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 869,618 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Robert Adelman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein."}],"balance_after":3969789,"source":{"system":"sec-edgar","filing":"0000905148-20-000827","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000090514820000827/form4.xml","form_type":"4"}},{"id":3078918,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":88848,"kind":"person","name":"Adelman Robert J","position":1,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":2,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127228,"kind":"organization","name":"venBio Global Strategic Fund II L.P.","position":4,"cik":"0001634632","reported_name":"venBio Global Strategic Fund II L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":5,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127229,"kind":"organization","name":"venBio Global Strategic GP II, L.P.","position":6,"cik":"0001729409","reported_name":"venBio Global Strategic GP II, L.P.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":127230,"kind":"organization","name":"venBio Global Strategic GP II, Ltd.","position":7,"cik":"0001729408","reported_name":"venBio Global Strategic GP II, Ltd.","relationship":{"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2020-07-22T01:29:11.000Z","date":"2020-07-21","kind":"exercise","acquired":true,"shares":78175,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F10","text":"Includes 18,231 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"The shares are held by Robert Adelman directly."}],"balance_after":96406,"source":{"system":"sec-edgar","filing":"0000905148-20-000827","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000090514820000827/form4.xml","form_type":"4"}},{"id":3572122,"issuer":{"id":6284,"kind":"organization","name":"PRECISION BIOSCIENCES INC","symbol":"DTIL"},"owners":[{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":1,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":2,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2019-04-01T17:35:14.000Z","date":"2019-04-01","kind":"exercise","acquired":false,"shares":998004,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's preferred stock converted into shares of the Issuer's common stock, $0.000005 par value per share, on a one-for-2.134686 basis upon the closing of the Issuer's initial public offering, after giving effect to the reverse stock split effected by the Issuer in connection with the initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's preferred stock converted into shares of the Issuer's common stock, $0.000005 par value per share, on a one-for-2.134686 basis upon the closing of the Issuer's initial public offering, after giving effect to the reverse stock split effected by the Issuer in connection with the initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's preferred stock converted into shares of the Issuer's common stock, $0.000005 par value per share, on a one-for-2.134686 basis upon the closing of the Issuer's initial public offering, after giving effect to the reverse stock split effected by the Issuer in connection with the initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"venBio Global Strategic GP, LP is the sole general partner of venBio Global Strategic Fund, LP and venBio Global Strategic GP, Ltd. is the sole general partner of venBio Global Strategic GP, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":467518},"source":{"system":"sec-edgar","filing":"0001012975-19-000254","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1770835/000101297519000254/edgar.xml","form_type":"4"}},{"id":3572121,"issuer":{"id":6284,"kind":"organization","name":"PRECISION BIOSCIENCES INC","symbol":"DTIL"},"owners":[{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":1,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":2,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2019-04-01T17:35:14.000Z","date":"2019-04-01","kind":"exercise","acquired":false,"shares":8000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's preferred stock converted into shares of the Issuer's common stock, $0.000005 par value per share, on a one-for-2.134686 basis upon the closing of the Issuer's initial public offering, after giving effect to the reverse stock split effected by the Issuer in connection with the initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's preferred stock converted into shares of the Issuer's common stock, $0.000005 par value per share, on a one-for-2.134686 basis upon the closing of the Issuer's initial public offering, after giving effect to the reverse stock split effected by the Issuer in connection with the initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's preferred stock converted into shares of the Issuer's common stock, $0.000005 par value per share, on a one-for-2.134686 basis upon the closing of the Issuer's initial public offering, after giving effect to the reverse stock split effected by the Issuer in connection with the initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"venBio Global Strategic GP, LP is the sole general partner of venBio Global Strategic Fund, LP and venBio Global Strategic GP, Ltd. is the sole general partner of venBio Global Strategic GP, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3747623},"source":{"system":"sec-edgar","filing":"0001012975-19-000254","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1770835/000101297519000254/edgar.xml","form_type":"4"}},{"id":3572120,"issuer":{"id":6284,"kind":"organization","name":"PRECISION BIOSCIENCES INC","symbol":"DTIL"},"owners":[{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":1,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":2,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-01T17:35:14.000Z","date":"2019-04-01","kind":"exercise","acquired":true,"shares":467518,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock converted into shares of the Issuer's common stock, $0.000005 par value per share, on a one-for-2.134686 basis upon the closing of the Issuer's initial public offering, after giving effect to the reverse stock split effected by the Issuer in connection with the initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"venBio Global Strategic GP, LP is the sole general partner of venBio Global Strategic Fund, LP and venBio Global Strategic GP, Ltd. is the sole general partner of venBio Global Strategic GP, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":4265141,"source":{"system":"sec-edgar","filing":"0001012975-19-000254","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1770835/000101297519000254/edgar.xml","form_type":"4"}},{"id":3572119,"issuer":{"id":6284,"kind":"organization","name":"PRECISION BIOSCIENCES INC","symbol":"DTIL"},"owners":[{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":1,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":2,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-01T17:35:14.000Z","date":"2019-04-01","kind":"exercise","acquired":true,"shares":3747623,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock converted into shares of the Issuer's common stock, $0.000005 par value per share, on a one-for-2.134686 basis upon the closing of the Issuer's initial public offering, after giving effect to the reverse stock split effected by the Issuer in connection with the initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"venBio Global Strategic GP, LP is the sole general partner of venBio Global Strategic Fund, LP and venBio Global Strategic GP, Ltd. is the sole general partner of venBio Global Strategic GP, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":3797623,"source":{"system":"sec-edgar","filing":"0001012975-19-000254","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1770835/000101297519000254/edgar.xml","form_type":"4"}},{"id":3572118,"issuer":{"id":6284,"kind":"organization","name":"PRECISION BIOSCIENCES INC","symbol":"DTIL"},"owners":[{"id":134220,"kind":"organization","name":"venBio Global Strategic Fund, L.P.","position":1,"cik":"0001504130","reported_name":"venBio Global Strategic Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":134221,"kind":"organization","name":"venBio Global Strategic GP, L.P.","position":2,"cik":"0001770834","reported_name":"venBio Global Strategic GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":134222,"kind":"organization","name":"venBio Global Strategic GP, Ltd.","position":3,"cik":"0001770835","reported_name":"venBio Global Strategic GP, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-01T17:35:14.000Z","date":"2019-04-01","kind":"purchase","acquired":true,"shares":50000,"price":16,"value":800000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"venBio Global Strategic GP, LP is the sole general partner of venBio Global Strategic Fund, LP and venBio Global Strategic GP, Ltd. is the sole general partner of venBio Global Strategic GP, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001012975-19-000254","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1770835/000101297519000254/edgar.xml","form_type":"4"}}]}